These studies encompassed diverse populations, including stroke survivors, apolipoprotein E (APOE) ɛ4 carriers, and individuals with metabolic syndrome, and examined both interventions, such as glucose-lowering therapies, and risk factors, including hypoglycemia and poor glycemic control. This evidence concerns the gene APOE and Stroke.